Calithera Biosciences (NASDAQ: CALA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.600 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Calithera Biosciences (NASDAQ: CALA) through any online brokerage.
Other companies in Calithera Biosciences’s space includes: Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), BioRestorative Therapies (NASDAQ:BRTX), Biophytis (NASDAQ:BPTS) and Diffusion Pharmaceuticals (NASDAQ:DFFN).
The latest price target for Calithera Biosciences (NASDAQ: CALA) was reported by Wells Fargo on Wednesday, May 11, 2022. The analyst firm set a price target for 2.00 expecting CALA to fall to within 12 months (a possible -23.08% downside). 6 analyst firms have reported ratings in the last year.
The stock price for Calithera Biosciences (NASDAQ: CALA) is $2.6 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Calithera Biosciences.
Calithera Biosciences’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Calithera Biosciences.
Calithera Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.